Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bellary, S.
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Inhaled insulin: overcoming barriers to insulin therapy?

Srikanth Bellary

Department of Medicine-Undergraduate Centre, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK

Anthony H Barnett

Department of Medicine-Undergraduate Centre, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK, anthony.barnett{at}heartofengland.nhs.uk

nhaled insulin is a new route of insulin delivery that can be used in the treatment of type 1 and type 2 diabetes. It offers an alternative and additional means of insulin administration, and has been received with particular satisfaction by patients who dislike injections. Trials indicate that inhaled insulin can be used effectively for pre-meal bolus intensification of treatment. Pre-meal inhaled insulin with Exubera® has shown faster absorption and similar duration of action to regular subcutaneous insulin with an overall similar glucodynamic effect. Although bioavailability is lower, mainly due to losses in the upper airways, this is compensated for by dose. The commonest side effect reported with inhaled insulin, as with subcutaneous insulin, was hypoglycaemia, almost a quarter of patients noted a cough which settled with continued treatment. Increased antibody titres and changes in lung function return to normal on discontinuation of inhaled insulin. Quality of life scores indicate patient preference for inhaled versus injected insulin, thus increased choice may improve adherence to treatment regimens. However, true cost:benefit analyses have to be undertaken as do studies in children, smokers and people with respiratory conditions, e.g. asthma.

Key Words: Exubera® • inhaled insulin • diabetes.

References

  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.[Abstract/Free Full Text]
  • Saydah SH, Fradkin J., Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;29:335-42.
  • Wright A., Burden AC, Paisey RB, Cull CA, Holman RR UK. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of Insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study. (UKPDS 57). Diabetes Care 2002;25:330-6.[Abstract/Free Full Text]
  • Zamanini A., Newson RB, Maisey M., Feher MD Injection related anxiety in insulin treated diabetes. Diab Res Clin Pract 1999;46:239-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hunt LM, Valenzuela MA, Pugh JA NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292-8.[Abstract]
  • Gerber RA, Hauber AB, Bolinder B., Johnson FR Diabetes patients' stated preference for insulin therapies: trading health for convenience. Diabetologia 2004;47(suppl 1):A274.
  • Chetty DJ, Chien YW Novel methods of insulin delivery: an update. Crit Rev Ther Drug Carrier Syst 1998;15:629-70.[Web of Science][Medline] [Order article via Infotrieve]
  • Byron PR Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv Drug Deliv Rev 1990;5:107-32.[CrossRef]
  • Gansslen M. Uber inhalation von insulin. Klin. Wochenschr 1925;4:71.
  • Wigley FW, Londono JH, Wood SH, Shipp JC, Waldman RH Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971;20:552-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Owens DR New horizons-alternative routes for insulin therapy. Nat Rev Drug Discov 2002;1:529-40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Laube BL The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50:1161-76.[Medline] [Order article via Infotrieve]
  • Klonoff DC Inhaled insulin. Diabetes Technol Ther 1999;1:307-13.[CrossRef][Medline] [Order article via Infotrieve]
  • Patton JS, Bukar JG, Eldon MA Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heinemann L., Traut T., Heise T. Time-action profile of inhaled insulin. Diabet Med 1997;14:63-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rave K., Bott S., Heinemann L. et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-82.[Abstract/Free Full Text]
  • Kapitza C., Hompesch M., Scharling B., Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004;6:466-72.[CrossRef][Medline] [Order article via Infotrieve]
  • Henry RR, Fountaine R., Willavize S., Fisher J., Fryburg D. Intrasubject variability of inhaled insulin comparable to subcutaneous regular insulin in patients with type 2 diabetes. Endocr Pract 2005;11(suppl 1):28-29. A884.
  • Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001;357:331-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Quattrin T., Belanger A., Bohannon NJ, Schwartz SL Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-7.[Abstract/Free Full Text]
  • Skyler JS, Weinstock RS, Raskin P. et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-5.[Abstract/Free Full Text]
  • Hollander PA, Blonde L., Rowe R. et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-62.[Abstract/Free Full Text]
  • Hermansen K., Ronnemaa T., Petersen AH, Bellaire S., Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162-7.[Abstract/Free Full Text]
  • Rosenstock J., Baughman RA, Rivera-Schaub T. et al. A randomised double blind, placebo controlled study of the efficacy and safety of Inhaled technosphere insulin in patients with type 2 diabetes. Diabetes 2005;54 (suppl 1):A88 [Abstract 357].
  • Garg S., Rosenstock J., Muchmore D., De L.a Pena A., Sun B., Silverman B. Safety and Efficacy of pre-prandial human insulin inhalation powder (HIIP) delivered by the Lilly/Alkermes inhaled insulin delivery system versus injectable insulin in patients with type 1 diabetes. Diabetes 2005;54 (suppl 1):A89[Abstract 361].
  • De Fronzo RA, Bergenstal RM, Cefalu WT et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922-8.[Abstract/Free Full Text]
  • Rosenstock J. Zinman B., Murphy LJ et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143:549-58.[Abstract/Free Full Text]
  • Skyler JS (For the inhaled insulin Phase 2 study group). Long term sustained efficacy and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia 2004;47(suppl 1):A311.
  • Barnett AH, Amiel SA, Hopkins D. Six month efficacy and 2-year safety of inhaled insulin as adjunctive therapy in combination with an oral agent. Diabet Med 2005;22(suppl 2):P82.
  • Dreyer M. (For the inhaled insulin Phase 3 study group). Efficacy and 2 year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral monotherapy. Diabetologia 2004;47(suppl 1):A44.
  • William T Cefalu, Marjana Serdarevic-Pehar, for Exubera Phase 3 study group. Long-term use of Exubera in type 2 diabetes: Observations on glycemic control, pulmonary function and anti-body formation. Diabetes 2005;54(suppl 1):A88.
  • Himmelmann A., Jendle J., Mellen A., Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003;26:677-82.[Abstract/Free Full Text]
  • Becker RH, Sha S., Frick AD, Fountaine RJ The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006;29:277-82.[Abstract/Free Full Text]
  • Dumas R., England RD, Reise RJ, Teeter JG Exubera is well tolerated and achieves tight glycemic control in patients with type 1 diabetes. Diabetes 2005;54(suppl 1):A87.[CrossRef]
  • Fineberg SE, Kawabata T., Finco-Kent D., Liu C., Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two year extension trial. J Clin Endocrinol Metab 2005;90:3287-94.[Abstract/Free Full Text]
  • Heise T., Bott S., Tusek C. et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: A prospective randomized pharmacodynamic study. Diabetes Care 2005;28:2161-9.[Abstract/Free Full Text]
  • Rosenstock J., Cappelleri JC, Bolinder B., Gerber RA Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23.[Abstract/Free Full Text]
  • Freemantle N., Blonde L., Duhot D. et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427-8.[Free Full Text]
  • Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001;24:1556-9.[Abstract/Free Full Text]
  • Testa MA, Turner RR, Hayes JF, Scranton RE, Simonson DC An international trial of sulfonylurea plus either metformin or inhaled insulin: Impact on quality of life and treatment satisfaction. Diabetologia 2004;47(suppl 1):A5.
  • Simonson DC, Turner RR, Hayes JF, Scranton RE, Testa MA Improving quality of life in type 2 diabetes when inhaled insulin is added after failure on metformin: A multicenter, international trial. Diabetologia 2004;47(suppl 1):A311.
  • Cappelleri JC, Cefalu WT, Rosenstock J., Kourides IA, Gerber RA Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002;24:552-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bilous R. Overall satisfaction increased more with inhaled insulin than with subcutaneous insulin in type 1 diabetes. ACP J Club 2002;136:101.[Medline] [Order article via Infotrieve]
  • Muller E., Maxion-Bergemann S., Bolinder B., Gerber RA, Bergemann R. EAGLE-Economic Assessment of Glycemic control and long term effects: A computer simulation model for diabetes mellitus type 1 and type 2. Diabetologia 2004;47(suppl 1):A355.[CrossRef]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3, 103-108 (2006)
DOI: 10.1177/14746514060060030201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
C. J Bailey and A. H Barnett
Why is Exubera being withdrawn?
BMJ, December 1, 2007; 335(7630): 1156 - 1156.
[Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
C. J Bailey, C. Day, and A. H Barnett
Exubera expires
The British Journal of Diabetes & Vascular Disease, November 1, 2007; 7(6): 255 - 256.
[PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
S. Bellary and A. H Barnett
Inhaled insulin (Exubera(R)): combining efficacy and convenience
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 179 - 185.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bellary, S.
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?